Kelli Dahlgren
Family · Corpus Christi, TXNPI 1821518200
Payments from drug & device makers
Across 294 payments — averaging $38.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$4K
- Novo Nordisk$1K
- Corcept Therapeutics$1K
- Lilly USA, LLC$737
- Medtronic$648
- Bayer$432
- plus $4K from 31 others
What the payments were for
- Consulting fees$3,00027%
- Travel & lodging$7607%
- Food & beverage$7,36566%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 10 | $3,638 |
| Novo Nordisk | 59 | $1,206 |
| Corcept Therapeutics | 38 | $1,039 |
| Lilly USA, LLC | 31 | $737 |
| Medtronic | 3 | $648 |
| Bayer | 19 | $432 |
| Boehringer Ingelheim | 21 | $366 |
| Mannkind Corporation | 5 | $356 |
| Novartis | 12 | $298 |
| Amgen(2 entities) | 13 | $294 |
| Recordati_rare_diseases_inc. | 9 | $251 |
| Madrigal Pharmaceuticals | 6 | $249 |
| Abbott | 10 | $178 |
| Xeris Pharmaceuticals, Inc. | 7 | $131 |
| Radius Health, Inc. | 4 | $128 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| Dexcom, Inc. | 7 | $124 |
| Tandem Diabetes Care, Inc. | 4 | $112 |
| Esperion Therapeutics, Inc. | 6 | $106 |
| Ascendis Pharma Endocrinology Inc | 3 | $102 |
| Angiodynamics, Inc. | 1 | $86 |
| AbbVie | 4 | $83 |
| Nevro Corp. | 1 | $79 |
| Amneal Pharmaceuticals LLC | 3 | $71 |
| Intercept Pharmaceuticals, Inc. | 1 | $64 |
| Insulet Corporation | 3 | $63 |
| BETA Bionics, Inc. | 1 | $34 |
| Sequel Med Tech, LLC | 2 | $32 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Chiesi USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| GSK | 1 | $19 |
| Henry Schein, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$3,364
- MINIMED 780G$613
- AFREZZA$250
- Korlym$233
- QUVIVIQ$124
- ZEPBOUND$122
- ISTURISA$120
- REZDIFFRA$113
- Ozempic$103
- RYBELSUS$103
How this compares
$11,213 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 260 | $330,612 |
| OzempicSemaglutide | 106 | $116,863 |
| JardianceEmpagliflozin | 67 | $65,450 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $57,628 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $39,623 |
| TrulicityDulaglutide | 27 | $29,855 |
| FarxigaDapagliflozin Propanediol | 16 | $15,436 |
| JanuviaSitagliptin Phosphate | 16 | $14,092 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $9,945 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 28 | $2,046 |
| SynthroidLevothyroxine Sodium | 20 | $1,300 |
| Levothyroxine Sodium | 79 | $692 |
| Rosuvastatin Calcium | 43 | $456 |
| Atorvastatin Calcium | 48 | $318 |
| Metformin Hcl ErMetformin Hcl | 20 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $737 | $360,467287 claims |
| Novo NordiskOzempic | $1,206 | $116,863106 claims |
| Boehringer IngelheimJardiance | $366 | $65,45067 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $21 | $39,62335 claims |
| MerckJanuvia | $12 | $14,09216 claims |
| AbbVieSynthroid | $83 | $1,30020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $69279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.